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Summain Immunocytochemistrv (ICC) has been used routinely to stain for p53 overexpression in a range of
human tumours. The underlying assumption has been that positive staining indicates a mutation in the p53
coding sequence. Recently. however. discordancy has been observed and the accuracy of ICC as a marker of
p53 gene mutation has been questioned. In this study of 109 colorectal adenocarcinomas. we compared ICC
staining with p53 gene mutations detected by single-strand conformation polymorphism (SSCP) analysis.
Concordancy between the two techniques was found in 69 of tumours. ICC-positive SSCP-negative cases
accounted for 2001/o of tumours and ICC-negative SSCP-positive cases for the remaining IlIo%. These results
caution against the assumption that p53 protein overexpression is always associated with a gene mutation.
Epigenetic phenomena may account for a significant proportion of ICC-positive tumours.
p53 was originally detected as a 53 kDa nuclear phospho-
protein co-immunoprecipitating with SV40 large T antigen
(Lane & Crawford. 1979: Linzer & Levine, 1979). It has since
been shown to have a sequence-specific DNA-binding capa-
bility which regulates entry into the S phase of the cell cycle
at a transcriptional level (Kern et al.. 1991). Both cytogenetic
(Muleris et al.. 1985) and restriction fragment length
polymorphism (RFLP) studies (Vogelstein et al.. 1989) have
shown that loss of the p53 gene is a common event in human
cancers. In addition to deletion of the gene, more recent
studies have shown that mutation of the p53 coding sequence
is also a common occurrence in a wide range of human
tumours (Nigro et al.. 1989: Hollstein et al.. 1991). Altera-
tions of the p53 gene are now known to be among the most
frequent genetic changes occurring in human malignancies
(Hollstein et al., 1991; Caron de Fromentel & Soussi. 1992).
Mutation or deletion of this gene effectively removes the
regulatory influence of wild-type p53 protein on cell pro-
liferation and may confer a growth advantage on a neoplastic
population. This has led researchers to hypothesise that alter-
ations in the p53 gene play a fundamental role in tumour
development and progression.
Mutations occur most often in four of the five
phylogenetically conserved regions of the p53 gene (Hollstein
et al.. 1991; Caron de Fromentel & Soussi, 1992). When
mutations occur within these regions they generally result in
an altered or 'mutant' p53 protein product. Although wild-
type p53 protein, because of its short half-life, is normally
present at very low levels in the cell, changes in conformation
brought about by mutation apparently stabilise the mutant
protein (Levine et al.. 1991). The resultant accumulation of
mutant protein may be detected by immunocytochemistry
(ICC). Overexpression of the p53 protein detected by ICC
has now been used in a large number of studies on various
tumour types as a marker of p53 gene mutation (Bartek et
al., 1991; Porter et al., 1992).
Although some studies have shown a good correlation
between ICC staining and the presence of mutations within
the p53 gene as detected by molecular analysis (Rodrigues et
al., 1990; Davidoff et al., 1991; Marks et al.. 1991; Kohler et
al.. 1992; Maestro et al., 1992; Somers et al., 1992; Thor et
al.. 1992). others have revealed varying degrees of discor-
dancy (Barton et al.. 1991; Allred et al.. 1993; Kohler et al..
1993). Indeed. the use of ICC as an indicator of p53 gene
mutation has been questioned (Wynford-Thomas. 1992). We
undertook the present study to correlate ICC staining with
p53 gene mutation in a large series of human colorectal
cancers. Mutations were detected by the single-strand confor-
mation polymorphism (SSCP) technique (Orita et al.. 1989)
and p53 overexpression by ICC using the monoclonal
antibody DO-7.
Materials and methods
Tumour specimens
A series of 109 surgically resected tumours were provided by
the general surgeons at Sir Charles Gairdner Hospital. These
consisted of 65 Dukes' stage B and 44 Dukes' stage C
adenocarcinomas. Specimens were grossly examined and por-
tions of tumour and adjacent normal mucosa were excised.
snap frozen immediately in liquid nitrogen and stored at
-80°C until required for DNA extraction. The remaining
tumour was fixed in neutral buffered formalin and embedded
in paraffin for histopathology and ICC. The tissue specimen
for SSCP analysis was taken from the centre of the tumour
mass, while the tissue section for ICC was cut no more than
-2 mm away from this site.
Immunocv tochemistrr
Paraffin sections were cut at S jzm, mounted on slides.
dewaxed for 10 mn in xylene. passed through alcohol and
washed in water. They were then rinsed with 0.2 M Tris-
buffered saline pH 7.6 (TBS) and endogenous peroxidase
removed by soaking in 3% hydrogen peroxide for 5 min.
Sections were incubated with a blocking solution of 1:5
normal swine serum and TBS for 20 min before application
of the primary antibody. monoclonal mouse anti-human p53
protein (Dako p53 protein DO-7) at 1:20 dilution. The slides
were incubated at room temperature overnight then washed
twice with TBS before a biotinylated second antibody. anti-
mouse Ig antibody (1:200) (Silenius Lab. Melbourne Aust-
ralia). was applied. Streptavidin-horseradish peroxidase
conjugate (Silenius Lab) was added (1:200) to all slides and
incubated for 1 h before washing twice with TBS. Chromo-
gen solution containing 6 mg of diaminobenzoate in 10 ml of
TBS 30% hydrogen peroxide was then added and colour
allowed to develop for 8 mmn before being stopped by wash-
ing in TBS. Preparations in which the primary antibody was
omitted were used as negative controls. All slides were
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evaluated by two observers (P.R. and B.D.) and positive
reactions required the presence of brown reaction product
within neoplastic cells. Reactions in adjoining normal or
adenomatous mucosa were also assessed. Tumours were clas-
sified as negative (no cells staining) or positive (any number
of cells staining). If positive, a subjective assessment of the
percentage of tumour cells staining was made.
Preparation ofgenomic DNA
Genomic DNA was prepared from frozen tissue by grinding
the specimen to a powder in liquid nitrogen using a mortar
and pestle. The powder was then dissolved in an extraction
buffer containing 0.5% SDS, 10 mM Tris-HCI pH 8, 100 mM
EDTA, 20 Lgml-' RNAse A and l00Lgml-' proteinase K.
Samples were digested overnight at 5O-C on a rotating wheel
apparatus and then extracted with phenol-chloroform-
isoamyl alcohol (25:24:1). DNA was precipitated with one-
quarter volume of 7.5 M ammonium acetate and three
volumes of 100% ice-cold ethanol, washed with 70% ethanol,
air dried and redissolved in O mM Tris-0.l mM EDTA to a
final concentration of 100 ng l-1.
Amplification by polymerase chain reaction
Exons 5-8 of the p53 gene were amplified separately using
the following oligonucleotides (Biotech International) as
pnmers:
Exon 5 5'-TCTTCCTGCAGTACTCCCCT-3'
5'-AGCTGCTCACCATCGCTATC-3'
Exon 6 5'-GATTGCTCTTAGGTCTGGCC-3'
5'-GCAAACCAGACCTCAGGCGG-3'
Exon 7 5'-TTGTCTCCTAGGTTGGCTCT-3'
5'-GCTCCTGACCTGGAGTCT-TC-3'
Exon 8 5'-TCCTGAGTAGTGGTAATCTA-3'
5'-GCTrGCTTACCTCGCTTAGT-3'
The standard reaction mixture (25gl) contained 0.4pM of
each primer, 3 mM magnesium chloride, 67 mM Tris-HCI
pH 8.8, 16.6 mM ammonium sulphate, 0.2 mM dNTPs,
0.2mg mlr- gelatin, 0.45% Triton X-100, 0.5pCi of [a-
3'P]dCTP and 0.2 units of Taq polymerase. Thermal cycling
began with an initial denaturation of Omin, during which
time 100 ng of template DNA was added to the reaction. At
least 5 min of denaturation time remained after the addition
of template DNA. The initial cycle was completed with 1 min
of annealing and 2 min ofextension. This was followed by 35
cycles of 30 s denaturation, min annealing and 2 min exten-
sion. A final extension of 10 min completed the cycling reac-
tions. Denaturation temperature was 94°C, annealing
temperatures were 62'C (exon 5), 6OYC (exons 6 and 7) and
55C (exon 8) and extension temperature was 72'C.
SSCP analysis
A 2 LI volume of PCR product was denatured in 5IlI of
formamide loading buffer (95% formamide, 10 mM EDTA,
0.05% bromophenol blue and 0.05% xylene cyanol) by boil-
ing for 10 min. Denatured samples were loaded onto 12%
acrylamide- 10% glycerol (99:1 acrylamide-bisacrylamide)
non-denaturing gels (800 mm high x 0.4mm thick), focused
at 2,500V for 5min and run at 1,900V for 20-24h. Gels
were then wrapped in Saran and exposed to X-ray film (Fuji)
with intensifying screens at - 80C for 18-48 h. Samples
displaying mutant bands were reamplified and run a second
time to confirm the existence of a mutation. Germ-line DNA
from patients displaying a mutation in their tumour DNA
were also amplified and run on SSCP gels to confirm the
mutation was somatically acquired.
Sequencing ofmutant bands
Mutant bands were excised from SSCP gels using the
autoradiograph as a positional template. DNA was eluted
from the gel slice by immersing in 100;LI of water overnight
at room temperature, precipitated with a quarter volume of
7.5 M ammonium acetate and two volumes of 100% isopro-
panol, washed with 70% ethanol, air dried and resuspended
in 20 tl of 10mM Tris-0.1 mM EDTA. The mutant DNA
was sequenced by a modification of the chain termination
method (Sanger et al., 1977) using a Gibco BRL cycle
sequencing kit. Reamplified mutant DNA was introduced as
template to a set of dideoxy sequencing reactions and sub-
jected to a repetitive series of temperature changes similar to
PCR. End-labelled primer was extended by these reactions to
dideoxy terminations and the sequence was obtained by
separating fragments on a 6% acrylamide-7 M urea denatur-
ing gel.
Resuas
Detection ofp53 gene mutations by SSCP analysis
A total of 109 colorectal carcinomas were screened by SSCP
for mutations within exons 5-8 of the p53 gene. Mutant p53
was identified by the presence of one or two extra bands
migrating above or below the normal single-stranded pro-
ducts (Figure 1). Occasionally mutant bands were also
detected between the single- and double-stranded bands and
are probably caused by normal/mutant heterodimers. In all
cases, normal p53 banding patterns were also observed. Since
previous work by our group has shown that p53 allelic loss
occurs in 75% of these tumours (Iacopetta et al., 1994), these
normal bands probably arise from either an admixture of
normal tissue adjoining the tumour sample and/or tumour
heterogeneity. All mutations were confirmed by reamplifying
samples and running on separate SSCP gels. Whenever the
tumour DNA revealed a p53 mutation, the corresponding
germ-line DNA was also analysed by SSCP. No germ-line
mutations were found, indicating that the changes were of
somatic origin.
Mutations were found in 37% (40/109) of carcinomas
(Table I). The distribution of these mutations was 41%
(17/41) in exon 5, 12% (5/41) in exon 6, 15% (6/41) in exon
7 and 32% (13/41) in exon 8. In one tumour (84T) two
mutations were found in exon 5 and another in exon 8.
Several of the most commonly occurring mutant bands
detected by SSCP were sequenced and found to contain
mutations at codons 175 and 248 (Table II), corresponding
to two of the previously identified 'hotspot' regions (Nigro et
al., 1989; Hollstein et al., 1991; Caron de Fromentel &
Soussi, 1992). None of the mutations we sequenced was
found to be a conservative basepair change. Because the
primers used in this study cross the intron-exon boundary,
splice donor/acceptor mutations should have been detected
by SSCP analysis. However, none of the mutations we
sequenced was in this region (Table II).
The sensitivity ofthe SSCP technique in identifying mutant
DNA in the presence of large amounts of normal DNA is
dependent on the resolution of the SSCP gel. Overexposure
of the gel will eventually reveal all aberrantly migrating
bands, providing they are sufficiently well separated from the
normal bands. To determine the sensitivity of our SSCP gels,
normal and mutant DNA bands from two different tumours
were excised, eluted, ampliied and rerun to confirm the
purity of these DNA templates. They were then diluted to
the same concentration and the normal and mutant alleles
mixed at varying ratios from 1.5% mutant DNA to 50%
mutant DNA. These mixes were amplified and run on SSCP
gels (Figure 2). In cases in which the aberrantly migrating
bands were well separated from the normal bands, as little as
1.5% mutant DNA in the original template mix could be
detected (Figure 2a). Even when the mutant bands migrated
close to normal bands, they could be detected in mixes
containing 6-12% mutant DNA template (Figure 2b).
In preliminary experiments, we optimised the sensitivity of
our SSCP gels by running PCR fragments from the same
tumour samples under widely varying conditions of tempera-
ture, buffer concentration, glycerol/acrylamide concentration,p53 ALTERATIONS IN COLON CANCER 587
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Fure I SSCP analysis of exons 5-8 of the p53 gene. Wild-type and two tumour samples containing mutations are shown for
each of the exons. Only single-stranded DNA bands are shown. Heterodimers and double-stranded bands have been omit-
ted.
run voltage and run duration. The running conditions we
selected resulted in good separation of all aberrantly migrat-
ing bands in each of the four exons.
Detection ofpS3 protein overexpression by
immunocytochemistry
The anti-p53 monoclonal antibody DO-7 recognises a de-
naturation-resistant epitope at the N-terminus of the human
p53 protein and reacts with both wild-type and mutant pro-
teins. We used DO-7 to detect p53 overexpression by ICC
staining of paraffin sections. In comparative studies using a
range of antibodies, DO-7 has been shown to be one of the
most sensitive for the detection of p53 overexpression (Cam-
pani et al., 1993; Jiko et al., 1993; Lassam et al., 1993; Baas
et al., 1994). Overall, 46% (50/109) of colorectal carcinomas
in this study exhibited positive nuclear staining (Figure 3).
Table I The relationship between p53 protein overexpression
detected by ICC and p53 gene mutation detected by SSCP analysis
of 109 colorectal carcinomas
SSCP SSCP
positive negative Total
ICC positive 28 (26%) 22 (20%) 50 (46%)
ICC negative 12 (11%) 47 (43%) 59 (54%)
Total 40 (370,) 69 (63%) 109 (100%)
Two cases also displayed small amounts of reaction product
in the cytoplasm of malignant cells. There was considerable
heterogeneity of positive ICC reactions throughout the series
and within individual tumours. The estimated percentage of
positively staining neoplastic cells in given tumours ranged
from 1 to 90%. No nuclear or cytoplasmic staining was
detected in normal tissue which adjoined 82% (89 109) of the
tumour sections.
The concordance of results between SSCP and ICC (i.e.
both positive or both negative) was 69% (75/109) (Table I).
A further 20% of carcinomas (22/109) stained positively by
ICC but failed to display any mutation by SSCP. while the
remaining 11% (12,'109) displayed mutant bands by SSCP
but showed no staining by ICC.
Diwcxs
Mutations of the p53 gene are the most common genetic
alteration. known to occur in a wide range of human cancers
(Hollstein et al., 1991). Under normal conditions wild-type
p53 protein is rapidly degraded and is therefore present only
at very low levels within the cell. The acquisition of a mutant
genotype is thought to increase the half-life of the mutant
protein and lead to its accumulation within the cell. This
accumulated protein is detectable by immunocytochemical
techniques and ICC has been proposed as an indirect method
of screening tumours for mutation within the p53 gene.
Recently however, a number of discordant results have been
Table I Characterisation of p53 mutations detected by SSCP analysis
Twnour Amino acid ICC
no. Exon Codon Mutation substitution staining'
12T 5 153 9 bp insertion
19T 7 242 4 bp insertion +
28T 5 175 G A Arg -His +
38T 5 175 G A Arg +His +
44T 7 248 C + T Arg- Trp +
47T 5 175 G-A Arg-*g His
54T 5 175 G-A Arg +His +
82T 5 175 C+T Arg-Cys
84Tr 5 173 Single bp deletion +
84Tb 5 186 Single bp deletion +
89T 5 175 G A Arg -His +
90T 5 152 C T Pro +Leu
95T 5 175 G-A Arg +His +
97T 6 214 T -G His +Gln
112T 7 254 Single bp insertion +
a_, negative staining by ICC; +, positive nuclear staining by ICC. bThis tumour
contained three separate mutations, two in exon 5 and one in exon 8.
0.
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a
Percentage mutant DNA
50% 25% 12% 6% 3% 1.5%
b
Percentage mutant DNA
50% 25% 12% 6% 3% 1.5%
Wild type
Mutant
Wild type
Fuzgue 2 The sensitivity of the SSCP technique was tested by
mixing mutant and normal DNA in varying proportions, amp-
lifying and then subjecting to SSCP analysis. a, When mutant
and normal bands were well separated, less than 1.5% mutant
DNA in the initial template mix could be detected. b, When
bands migrated more closely together approximately 6-12%
mutant DNA was required for detection.
reported (Barton et al., 1991; Wynford-Thomas, 1992; Alfred
et al., 1993; Kohler et a!., 1993). In the present study we have
attempted to address this issue by comparing p53 gene muta-
tion and protein overexpression in a large number of colorec-
tal tumours.
The frequency of p53 gene mutation detected by SSCP
analysis in our study was 37% (40/109) in primary colorectal
carcinomas, a frequency similar to recent molecular studies
on large numbers of colorectal cancers (Kikuchi-Yanoshita et
a!., 1992; Lothe et al., 1992). Compared with the study by the
Japanese group (Kikuchi-Yanoshita et al., 1992) we found
3-fold more mutations in exon 8 and 3-fold fewer in exon 7,
possibly reflecting exposure to different dietary or environ-
mental carcinogens. As described in the results (Figure 2), we
believe that the high resolution of our SSCP analysis allowed
the identification of tumours containin very low levels of
mutant p53 allele. For this reason we conclude that approxi-
mately 40% of colorectal carcinomas have at least some cells
carrying mutations within exons 5-8 of the p53 gene (Table
I).
T'he frequency of p53 protein overexpression detected using
ICC on the same series of colorectal carcinoma specimens
used for SSCP analysis was 46% (50/109). This is very
similar to the range of 42-49% reported in previous ICC
studies (Purdie et al., 1991; Scott et al., 1991; Cunninghmet
al., 1992; Starzynska et a!., 1992; Sun et a!., 1992; Bell et a!.,
1993). Because of the variety of methods used (different
antibodies, detection systems, tissue fixation, etc.) it is often
Fuu 3 Immunocytochemical staining of colorectal carcinomas
with the anti-p53 antibody DO-7. Neoplastic tissue shows strong
nuclear staining, whereas adjacent normal tissue shows no reac-
tion product.
difficult to make a direct comparison between the results
obtained by different groups. However, the DO-7 antibody
we used appears to give the same staining profile as two
other commonly used p53 antibodies, 1801 (Campani et al.,
1993; Lassam et al., 1993) and CM-1 (Jiko et al., 1993). A
comparative study of six different anti-p53 antibodies has
shown DO-7 to be the most sensitive and specific for ICC
detection of p53 protein in colorectal cancers (Baas et al.,
1994).
Although the frequencies ofp53 gene mutation and protein
overexpression we observed were quite similar (37% and
46% respectively), the concordancy of results from the two
techniques (i.e. both positive or both negative) was only 69%
(75/109). Recently, Allred et al. (1993) reported 62%
concordance between SSCP and ICC detection of p53 muta-
tion in breast cancer. As proposed by these authors and
others who have observed discrepancies between p53 gene
mutation and protein overexpression (Borresen et al., 1991;
Wynford-Thomas, 1992; Oliner et al., 1993; Slingerland et
al., 1993), several explanations could account for these
findings. Firstly, for the group of SSCP-negative/ICC-
positive tumours, (20% of cases) some mutations may have
occurred outside exons 5-8. We believe that this is unlikely
to account for all cases, however, especially in view of the
very low frequency (<5%) of mutations known to occur
outside the highly conserved regions of the p53 gene (Holl-
stein et al., 1991; Caron de Fromentel & Soussi, 1992).
Nevertheless, some of the tumours classified as SSCP
negative may contain a mutation outside of exons 5-8.
Masking of mutant DNA owing to the presence of large
amounts of normal tissue or because of heterogeneity within
individual tumours may also account for some of the SSCP-
negative/ICC-positive cases. However, the SSCP technique
has proven to be very sensitive in our hands, and when
mutant and normal bands are well separated a mutant DNA
content of as little as 1.5% is adequate for detection (Figure
2a). When mutant and normal bands were less well separated
a higher mutant DNA content of about 6-12% was required
for detection (Figure 2b).
In addition, the SSCP technique may not be 100% sen-
sitive, and therefore some mutations may have escaped detec-
tion. Another explanation for SSCP-negative/ICC-positive
cases is that p53 protein may accumulate in the absence of
gene mutation by forming complexes with other molecules
(Lane & Crawford, 1979; Sarnow et al., 1982; Momand et
al., 1992). This sequestered protein may be functionally inac-
tive but still detectable by p53 antibodies.
We observed 12 cases (11%) of SSCP-positive/ICC-nega-
tive tumours. The most likely explanations for these are,
firstly, that the mutations do not lead to protein stabilisation
Wild type
Mutant
Mutant
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and hence accumulation in the cell. Secondly, the mutated
gene may code for a stop codon and lead to production of a
truncated form of the protein or a halt in protein production
altogether. Thirdly, the antibody used for the ICC staining
may not have detected all mutant protein epitopes. We
sequenced five of these 12 cases (12T, 47T, 82T, 90T and
97T) and found that four had mutations leading to amino
acid substitutions and the fifth was a frameshift mutation
which introduced a stop codon downstream (Table II).
Despite the 31% (34/109) discordancy, the overall correla-
tion between SSCP and ICC detection of p53 mutations is
still highly significant (P<0.001). Wider screening for muta-
tions outside of the conserved gene regions and the use of
other antibodies in ICC staining are likely to have uncovered
other mutations which would have reduced this percentage.
Nevertheless, our results suggest that ICC detection of p53
protein overexpression does not always indicate the existence
of an underlying gene mutation and vice versa. This observa-
tion in colorectal cancer confirms other recent studies in large
numbers of lung cancer cell lines (Bodner et al., 1992) and
primary breast cancers (Allred et al., 1993). As suggested
previously (Bodner et al., 1992), overexpression of p53 pro-
tein may depend upon the type of gene mutation.
An obvious question which arises from this work is the
comparative biological significnce, if any, of p53 gene muta-
tions and protein overexpression in neoplasia. It has been
suggested that ICC detects functionally significant mutations
(Wynford-Thomas, 1992). Certainly, in breast cancer, over-
expression of p53 appears to be a significant marker of poor
prognosis (Isola et al., 1992; Thor et al., 1992; Allred et al.,
1993; Silvestrini et al., 1993). In colorectal cancer, however,
the association between ICC positivity and patient survival is
still controversial (Scott et al., 1991; O'Connell et al., 1992;
Remvikos et al., 1992; Starzynska et al., 1992; Sun et al.,
1992; Yamaguchi et al., 1992; Bell et al., 1993). Much less
work has been done correlating p53 gene mutation and
outcome. Two studies in breast cancer indicate poorer prog-
nosis in the presence of p53 gene mutation (Allred et al.,
1993; Thorlacius et al., 1993), but to our knowledge none has
been published so far on colorectal carcinoma. Although the
post-operative follow-up time of patients whose tumours
were examined in the current study is still quite short
(average 30 months), our preliminary results show no
significant correlation between p53 gene mutation and sur-
vival (Dix et al., 1994).
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